Miriam Bockmann
Overview
Explore the profile of Miriam Bockmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turewicz M, May C, Ahrens M, Woitalla D, Gold R, Casjens S, et al.
Proteomics
. 2013 Apr;
13(14):2083-7.
PMID: 23616427
Contemporary protein microarrays such as the ProtoArray® are used for autoimmune antibody screening studies to discover biomarker panels. For ProtoArray data analysis, the software Prospector and a default workflow are...
2.
Grottrup B, Bockmann M, Stephan C, Marcus K, Grinberg L, Meyer H, et al.
Proteomics
. 2012 Feb;
12(3):356-8.
PMID: 22290803
The HUPO Brain Proteome Project (HUPO BPP) held its 16th workshop in Geneva, Switzerland, on September 5, 2011 during the 10th HUPO World Congress. The focus was on launching the...
3.
Grottrup B, Bockmann M, Marcus K, Wiltfang J, Grinberg L, Meyer H, et al.
Proteomics
. 2011 Nov;
11(22):4279-83.
PMID: 22045679
The HUPO Brain Proteome Project (HUPO BPP) held its 15th workshop in Bochum, Germany, from April 8th to 9th, 2011 directly after the Proteomic Forum 2011 in Berlin. Like on...
4.
Zboralski D, Warscheid B, Klein-Scory S, Malas M, Becker H, Bockmann M, et al.
Mol Cancer
. 2010 Mar;
9(1):65.
PMID: 20307265
Background: Functional loss of the tumor suppressor Smad4 is involved in pancreatic and colorectal carcinogenesis and has been associated with the acquisition of invasiveness. We have previously demonstrated that the...
5.
Zboralski D, Bockmann M, Zapatka M, Hoppe S, Schoneck A, Hahn S, et al.
BMC Cancer
. 2008 Jul;
8:215.
PMID: 18664273
Background: Functional inactivation of the tumor suppressor Smad4 in colorectal and pancreatic carcinogenesis occurs coincident with the transition to invasive growth. Breaking the basement membrane (BM) barrier, a prerequisite for...
6.
Bockmann M, Hilken G, Schmidt A, Cranston A, Tannapfel A, Drosten M, et al.
Hum Gene Ther
. 2005 Nov;
16(11):1267-75.
PMID: 16259560
The efficient and specific introduction of genes into cancer cells in vivo remains a major challenge for current gene therapy modalities. Peptides possess appropriate properties to serve as tumor-targeting agents....
7.
Bockmann M, Drosten M, Putzer B
J Gene Med
. 2004 Oct;
7(2):179-88.
PMID: 15508130
Background: Adenovirus efficiently infects a broad range of target cells, thereby preventing selective gene transfer. Moreover, several cell types and tissues including primary tumors are refractory to adenoviral infection, mainly...
8.
Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston A, et al.
J Natl Cancer Inst
. 2004 Aug;
96(16):1231-9.
PMID: 15316058
Background: Dominant-activating mutations in the RET protooncogene, a receptor tyrosine kinase, have been identified as a cause of medullary thyroid carcinoma. Such oncogenic RET mutations induce its ligand-independent constitutive trans-autophosphorylation....